Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KeraVision

This article was originally published in The Gray Sheet

Executive Summary

Ad campaign for Intacs intrastromal corneal ring segments to treat mild nearsightedness commences the week of May 15 in 20 U.S. cities. The device gained FDA approval last year (1"The Gray Sheet" April 19, 1999, p. 12). The company plans to spend up to $5 mil. for radio, print and direct mail ads in the consumer campaign, the company says in a May 18 release

You may also be interested in...



KeraVision Eying Over 200 U.S. Centers With 3 Intacs Distribution Deals

KeraVision began its roll-out of Intacs intrastromal ring segments less than a week following FDA approval April 9, backed by distribution agreements with three major U.S. outlets serving over 200 eye care centers.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

UsernamePublicRestriction

Register

MT013408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel